BMY
Bristol-Myers Squibb Company
October 15, 2026 · market open
- Rarity
- 1.28
- Peak move
- +4.91%
- Float cap
- $120.3B
Bristol-Myers Squibb Company is a biopharmaceutical company that discovers, develops, licenses, manufactures, markets, distributes, and sells innovative medicines for serious diseases. Its therapies target oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. Products are sold worldwide, primarily to wholesalers, distributors, specialty pharmacies, and, to a lesser extent, retailers, hospitals, clinics, government agencies, and patients.
Where do you see this going?
no votes yetVoting closed at 4:00 PM ET.
What we found
13 events · 0 from SEC or newswire · 0 timed with the moveinstitutional_flowViking Fund Management LLC cut its Bristol-Myers Squibb stake by 15.8% in the third quarter, selling 70,000 shares and retaining 373,000 shares valued at about $23.3 million.
clinical_readoutBristol Myers Squibb reported positive topline Phase 3 EXCALIBER-RRMM results for Zenbexus (iberdomide) plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma, meeting the PFS primary endpoint with a 51% reduction in risk of disease progression or death versus the active comparator.
regulatory_approvalChina's NMPA Center for Drug Evaluation accepted Bristol Myers Squibb's Class 2.4 marketing application for a new indication of mavacamten capsules and proposed it for priority review for symptomatic obstructive hypertrophic cardiomyopathy in patients aged 12 and older.
analyst_ratingWells Fargo lowered its price target on Bristol-Myers Squibb to $60 from $65 while maintaining an Equal Weight rating, citing Eliquis loss of exclusivity in major EU markets in mid-November and questions on admilparant efficacy and safety.
analyst_ratingJefferies adjusted its price target on Bristol-Myers Squibb to $76 from $73, reiterating a Neutral rating.
analyst_ratingSanford C. Bernstein reiterated a Market Perform rating and $61.00 price target on Bristol-Myers Squibb following the company's admilparant ALOFT-IPF data, noting the 60 mg dose succeeded while the 120 mg dose did not.
patent_cliffBristol-Myers Squibb management said Eliquis will lose market exclusivity in mid-November 2026 in some major European Union markets, with a rapid sales decline expected afterward, while reaffirming current Eliquis guidance.
analyst_ratingMorgan Stanley analyst Terence Flynn maintained a Sell rating on Bristol-Myers Squibb with an unchanged $41 price target, citing modest clinical benefit from admilparant's Phase 3 data and an inverted dose-response.
clinical_readoutBristol Myers Squibb reported positive Phase 3 results for RYZ101 in gastroenteropancreatic neuroendocrine tumours, with the study meeting its primary endpoint, alongside the admilparant IPF readout.
clinical_readoutBristol Myers Squibb reported that its Phase 3 ALOFT-IPF trial of admilparant met its primary endpoint, with the 60 mg twice-daily dose showing a statistically significant improvement in forced vital capacity at Week 52 versus placebo while the 120 mg dose did not reach significance.
clinical_readoutBristol Myers Squibb reported positive topline interim Phase 3 ACTION-1 results for RYZ101 (225Ac-DOTATATE), RayzeBio's actinium-225 radiopharmaceutical, which met the primary endpoint with significantly extended progression-free survival versus investigator-chosen standard of care in SSTR-positive gastroenteropancreatic neuroendocrine tumors progressing after lutetium-177 therapy.
peer_disclosureContineum Therapeutics (NASDAQ:CTNM), which holds a Phase 2 LPA1 program against the same target as BMS' admilparant, saw its shares fall sharply after Bristol Myers' mixed ALOFT-IPF readout.
analyst_ratingBank of America lowered its price target on Bristol Myers Squibb to $66.00 on October 9, 2026.